CTXR
Another round of financing
Citius Pharmaceuticals said it entered a definitive deal to sell about 5.1 million shares of common stock — or pre-funded warrants instead — in a registered direct offering priced at-the-market under Nasdaq rules. The tab: roughly $5 million.
Why you should care
This is the classic biopharma balancing act: companies need cash to keep the lights on and fund the pipeline, but the easiest path is often more shares. That can help the business survive and advance programs, while also making every existing share a little less precious.
The fine print investors always hate reading
The shares were priced at $0.985 apiece, which tells you this wasn’t exactly a victory lap moment for the stock. Deals like this can be a useful lifeline, but they also tend to pressure the share price when traders start doing the dilution math.
Big picture
For Citius, the money may buy time. For shareholders, it’s another reminder that in biotech, the capital markets can be just as important as the lab.